

# Immunomodulators

Last Updated: February 29, 2024

Summary Recommendations
<ul style="list-style-type: none"><li>• The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. See <a href="#">Therapeutic Management of Hospitalized Adults With COVID-19</a> and <a href="#">Therapeutic Management of Hospitalized Children With COVID-19</a> for the COVID-19 Treatment Guidelines Panel's (the Panel) recommendations on the use of the following immunomodulators in hospitalized patients with COVID-19 according to their disease severity (listed in alphabetical order):<ul style="list-style-type: none"><li>• Abatacept</li><li>• Baricitinib (or tofacitinib)</li><li>• Dexamethasone</li><li>• Infliximab</li><li>• Tocilizumab (or sarilumab)</li></ul></li><li>• There is insufficient evidence for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19:<ul style="list-style-type: none"><li>• Anakinra</li><li>• Inhaled corticosteroids</li><li>• Vilobelimab</li></ul></li><li>• The Panel <b>recommends against</b> the use of <b>canakinumab</b> for the treatment of COVID-19, except in a clinical trial (BIIa).</li></ul> <p>Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See <a href="#">Guidelines Development</a> for more information.</p>